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Adequate bony support is the key to re-establish both function and esthetics in the craniofacial region. Auto-
logous bone grafting has been the gold standard for regeneration of problematic large bone defects. However,
poor graft availability and donor-site complications have led to alternative bone tissue-engineering approaches
combining osteoinductive biomaterials and three-dimensional cell aggregates in scaffolds or constructs. The goal
of the present study was to generate novel cell aggregate-loaded macroporous scaffolds combining the os-
teoinductive properties of titanium dioxide (TiO2) with hydroxyapatite–gelatin nanocomposites (HAP-GEL) for
regeneration of craniofacial defects. Here we investigated the in vivo applicability of macroporous (TiO2)-
enriched HAP-GEL scaffolds with undifferentiated and osteogenically differentiated multipotent adult pro-
genitor cell (MAPC and OD-MAPC, respectively) aggregates for calvaria bone regeneration. The silane-coated
HAP-GEL with and without TiO2 additives were polymerized and molded to produce macroporous scaffolds.
Aggregates of the rat MAPC were precultured, loaded into each scaffold, and implanted to rat calvaria critical-
size defects to study bone regeneration. Bone autografts were used as positive controls and a poly(lactic-
co-glycolic acid) (PLGA) scaffold for comparison purposes. Preimplanted scaffolds and calvaria bone from pig
were tested for ultimate compressive strength with an Instron 4411 and for porosity with microcomputerized
tomography (mCT). Osteointegration and newly formed bone (NFB) were assessed by mCT and nondecalcified
histology, and quantified by calcium fluorescence labeling. Results showed that the macroporous TiO2-HAP-
GEL scaffold had a comparable strength relative to the natural calvaria bone (13.8 – 4.5 MPa and 24.5 – 8.3 MPa,
respectively). Porosity was 1.52 – 0.8 mm and 0.64 – 0.4 mm for TiO2-HAP-GEL and calvaria bone, respectively.
At 8 and 12 weeks postimplantation into rat calvaria defects, greater osteointegration and NFB were significantly
present in the TiO2-enriched HAP-GEL constructs with OD-MAPCs, compared to the undifferentiated MAPC-
loaded constructs, cell-free HAP-GEL with and without titanium, and PLGA scaffolds. The tissue-engineered
TiO2-enriched HAP-GEL constructs with OD-MAPC aggregates present a potential useful therapeutic approach
for calvaria bone regeneration.
Introduction
Craniofacial bone is essential in providing protectionfor internal organs (brain), and support for facial soft
tissues. Annually, 2.3 million excision procedures for bone
graft replacement are performed. Craniofacial surgical pro-
cedures are among the most common regenerative proce-
dures.1 Major conventional substitutes for bone replacement
in the craniofacial region include autogenous, allogeneic, and
alloplastic or synthetic grafts. Autogenous grafts are well-
known clinical gold standards; however, complications from
donor excision sites may arise, as well as poor availability to
repair large defects and lack of formability (ability to shape
to a defect).2 Secondly, allogeneic grafts from freeze-dry bone
banks present immunogenic risks and are devoid of a cell
reservoir that contributes to the formation of new bone.3,4
These limitations increased the focus of bioengineers on al-
loplastic grafts.3,4
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The purpose of this study was to investigate whether
hydroxyapatite–gelatin (HAP-GEL) alloplastic materials can
be used as a bone replacement porous scaffold/construct to
carry three-dimensional (3D) cell aggregates.5 HAP-GEL
cross-linked with an aminosilane was previously found to
exhibit an appropriate compressive strength (100 MPa), bio-
compatibility and facilitate surface bone ingrowth.6,7 The
loading of cells on alloplastic grafts such as porous calcium-
based scaffolds in the hydroxyapatite form (HAP), followed
by in vivo implantation in large bone defects, had been pre-
viously shown to promote healing.8,9 Moreover, injectable
and formable calcium-based composites with natural poly-
meric phases (e.g., gelatin) can further increase their clinical
applicability.10
Titania additives may constitute an advantage by in-
creasing surface hydrophobicity and protein adsorption to
further enhance cell adhesion, osteogenic induction, and
formability in bone biomaterials, including in HAP-GEL.7,11,12
Consequently, bone regeneration of formable titanium dioxide
(TiO2)-enriched HAP-GEL scaffolds was compared in this
study to HAP-GEL alone.
HAP-based scaffolds have been successfully combined with
stem cells to shorten the in vivo bone-healing time when
compared to cell-free HAP.5,13 Porous HAP-GEL scaffolds
loaded with multipotent adult progenitor cells (MAPCs), a
subpopulation of cells isolated from rat bone marrow, have
recently been implanted in vivo in large bone defects. The
construct was shown to be feasible to carry these MAPCs in 3D
aggregates.5 MAPCs hold important advantages over mes-
enchymal stem cells (MSC) in terms of homogeneity of surface
markers.14,15 They also have high levels of the Oct4 transcrip-
tion factor, a high growth rate, and are able to be grown as 3D
aggregates.16,17 MAPCs are also capable of forming the three
germ lineages, including the mesoderm that gives rise to bone
tissue when dexamethasone is supplemented.18,19 Recent
studies demonstrate that clinical grade human MAPCs (Mul-
tistem) offer clinical relevance for the treatment of autoim-
mune disorders and cardiac infarction (ClinicalTrials.gov
NCT00677859, NCT00677222); however, no in vivo applicabil-
ity studies for bone regeneration have been reported.
Here we report an in vivo MAPC-based bone regeneration
model employing a novel 3D aggregate culture system, re-
cently shown by our group to promote in vitro osteogenic
differentiation.5 To study the in vivo applicability of MAPC
aggregates in macroporous constructs, we evaluated whe-
ther TiO2-enriched HAP-GEL scaffolds loaded with MAPC
3D aggregates increase bone regeneration when compared to
unloaded scaffolds. Since osteogenically differentiated cells
may generate more newly formed bone (NFB) than uncom-
mitted progenitor cells,5,20 we tested whether rigid scaffolds
with osteogenically differentiated MAPC (OD-MAPCs)
aggregates produce more new bone than scaffolds with un-
differentiated MAPCs. To accomplish these aims, a critical-
size defect (CSD) model in rat calvaria was used to implant
different HAP-GEL/MAPC constructs.
Materials and Methods
Fabrication of HAP-GEL macroporous scaffolds
for calvaria defects
The HAP-GEL biomaterial was fabricated using biomi-
metic synthesis as described in previous studies.6,7,21 Briefly,
the HAP coprecipitation reaction was induced at 38C in
soluble GEL titrated with the Ca(OH)2 solution. After the
coprecipitation, the slurry was centrifuged and the super-
natant removed. The condensed HAP-GEL slurry was then
washed. The HAP-GEL precipitant was lyophilized and
crosslinked with 11% weight enTMOS (bis[3-(trimethox-
ysilyl)-propyl]ethylenediamine). Phosphate-buffered saline
1 · (16% of total weight) was added to confer injectability
properties to the final HAP-GEL. Next, the HAP-GEL paste
was loaded into a 1 cc syringe with a nasal diameter of 1 mm.
To fabricate the dorsal cap that will hold the porous phase
(Fig. 1), the paste was packed into a 12.7 · 2 mm cylindrical
custom-made polypropylene mold. To develop the porous
phase, the HAP-GEL paste was injected without packing in a
spaghetti form over the dorsal cap to generate the macro-
porosity for cell retention and growth (Fig. 1). The scaffold
was allowed to solidify, and then sent for gas sterilization. To
fabricate TiO2-enriched HAP-GEL scaffolds, a similar pro-
cedure was followed, but this time, TiO2 (Evonik Aeroxide
P25) was added to the HAP-GEL (at silica:titanium atomic
ratio of 60:40) before molding, as reported previously.5,7
Porosity of HAP-GEL scaffolds
HAP-GEL scaffolds (8 mm diameter · 3 mm thickness) with
and without titania, and same-size specimens from natural
calvaria bone from pig were scanned and evaluated by mi-
crocomputed tomography (mCT). The mCT scanning was
performed with a Portable Skyscan 1074mCT System (Micro
Photonics). The X-ray parameters were 40 kV at 1 mA with
420 ms-exposure time, and a spatial resolution of *22mm. The
image matrix size was 768 · 576 pixels with acquired 2000
projections over a 360 rotation. All samples were positioned
and scanned in a standard manner using an air-tight cylin-
drical sample holder. For the analysis of the acquired images,
the CTAn analyser software (Micro Photonics) was used to
measure the mean pore size. ImageJ software (NIH) was used
to determine the scaffold and bone specimen porosity fraction
(in%). Five specimens were analyzed for each HAP-GEL
scaffold group (with and without titania).
Mechanical testing of HAP-GEL scaffolds
For compressive testing, macroporous HAP-GEL scaffolds
with and without titania (8 · 3 mm) were compared to the
FIG. 1. Schematic representation of the macroporous and
solid components of the hydroxyapatite–gelatin (HAP-GEL)
scaffold (A) implanted in the 8-mm-critical-size defect (CSD)
in rat calvaria.
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same size: (1) natural calvaria bone specimens from pig and
(2) porous collagen scaffolds (Nitta Gelatin, Inc.). All samples
were compressed using an Instron 4411 (Instron Co.) at
0.5 mm/min to determine the ultimate compressive strength.
Five specimens were analyzed per group.
Aggregate MAPC culture, viability,
and osteogenic differentiation
Rat MAPCs were isolated from bone marrow and were
depleted of CD45 and Ter119 after 4 weeks in hypoxia cul-
ture conditions using magnetic microbeads and the remain-
ing cells were seeded. After 3–14 weeks, cells with a typical
spindle-shaped MAPC morphology appeared. Hypoxia
conditions (incubator at 37C with 5% O2 and 5%–6% CO2)
were used to optimize MAPC expansion. To confirm that
these clones were in fact MAPCs, the level of Oct4 mRNA
was determined using quantitative real-time polymerase
chain reaction and the presence of CD31, typical for MAPCs,
was analyzed by fluorescence-activated cell sorting. Once
a cell line with the MAPC phenotype (Oct4 mRNA at DCT
of 4–6, and CD31 + ) was derived, a large frozen work-
ing cell bank was prepared. The characteristics of the puta-
tive MAPCs were then evaluated (endothelial, hepatocyte,
and neural precursor-like differentiation, and further tran-
scriptome phenotype) as described previously.15,17 During
subsequent cell expansion, quality control studies were per-
formed up to passage 30. Rat MAPCs from passage 20 were
used for all the experiments of this study.
When osteogenic differentiation media were supple-
mented, cell cultures were changed to normal O2 levels. For
the 3D aggregate system, 1–2 · 103 MAPCs were seeded in
suspension with the MAPC growth medium in 96-well-
rounded bottom ultralow attachment plates (Costar #7007;
Corning, Inc. Life Sciences), using a modification of a forced
aggregation method previously reported.5,17 The well plates
were centrifuged to allow cells to settle to the bottom of the
well and form aggregates over time. Aggregates were al-
lowed to grow for 4 days in growth media, and then 10
undifferentiated aggregates were transferred and loaded into
HAP-GEL scaffolds. Cell viability was assessed before in vivo
implantation. A Live/Dead Cell Vitality Assay kit (L34951;
Molecular Probes) was used to confirm cell-active metabo-
lism and viability according to the manufacturer’s instruc-
tions. Metabolically active cells stained red fluorescent, and
dead cells stained green. Fluorescence was visualized by
microscopy with a Nikon Eclipse Ti-U with a digital camera,
and Nikon NIS Elements software was used to render im-
ages (Nikon).
To generate OD-MAPCs, the MAPC osteogenic differen-
tiation process was initiated in vitro by transferring 10 un-
differentiated 3D aggregates to each well on 24-well ultralow
attachment plates (Costar) with the osteogenic medium with
dexamethasone. This 3D culture system and medium have
been previously confirmed in our recent studies to be effec-
tive for MAPC osteogenic differentiation.5 The osteogenic
medium was composed of the MAPC basal medium with the
addition of 10 mM of b-glycerophosphate (Sigma), ascorbic
acid at 0.2 mM (Sigma), and dexamethasone at 10 - 7 M
(Sigma).15 The medium was changed every 2–3 days. The
MAPCs were cultured for 38 days, and osteogenic differen-
tiation was confirmed by (1) evaluating in vitro mineraliza-
tion with crystal nucleation/formation in matrices by
transmission electron microscopy (TEM); (2) assessing the for-
mation of mineralized nodules with Alizarin Red; and (3) the
presence of bone-specific markers (collagen type I, osteopontin,
and osteocalcin) by immunohistochemistry in cryosectioned
cell aggregate matrices, as previously described.5 Then, 10
FIG. 2. Electron and fluorescence microscopy and microcomputerized tomography (mCT) images of osteogenically differ-
entiated multipotent adult progenitor cell (OD-MAPC) aggregates/matrices and scaffolds. Top panel: In vitro mineralization
of OD-MAPC aggregates/matrices seen in transmission electron microscopy (TEM) preimplantation (A) and cell viability of
aggregates after transferring into macroporous HAP-GEL scaffolds (B). Bottom panel: three-dimensional (3D) mCT image of
the macroporous HAP-GEL scaffolds (C), and mCT images comparing the porosity of macroporous HAP-GEL scaffolds (D)
with calvaria natural bone (E) 2D cross sections. (A) TEM Mag.: 80,000 · ; (B) viable cells: red; nonviable cells: green-yellow;
scale bar is 200mm; Mag.: 100 · ; (C–E): scale bar is 1.0 mm. Color images available online at www.liebertpub.com/tea
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osteogenically differentiated aggregates from culture day
38 were loaded into the macroporous TiO2-HAP-GEL scaf-
folds.
In vivo implantation of macroporous HAP-GEL
scaffolds with MAPC aggregates
Craniofacial defects consisted of 8-mm-diameter calvaria
CSD (Fig. 1), which have been previously described.22–24
Briefly, 11- to 13-week-old Sprague-Dawley rats (Charles
River) were anesthetized and a CSD was created on the
calvaria bone using a dental trephine drill. Calvaria defects
were assigned to the following experimental groups listed in
Table 1. Porous collagen and poly(lactic-co-glycolic acid)
(PLGA) scaffolds (Nitta Gelatin, Inc.) were used in this
study as gold standard controls since both have been rou-
tinely placed to regenerate craniofacial and other orthope-
dic defects.1–3,25,26 The sample size per group was equal to
three. Two fluorochrome dyes were administered to evalu-
ate the impact of different scaffolds on bone-healing rates27:
(1) Alizarin Red S 30 mg/kg, (2) calcein, 20 mg/kg. Fluor-
ochromes were administered to each animal by perivascular
injection. Each rat received labels twice during the study. The
first label (Alizarin Red) was given 10 days after the surgery,
and the second (calcein) was given 15 days before sacrifice.
There were interlabeling periods of 10 and 42 postsurgical
days for rats sacrificed at 8 weeks and 10 and 70 days for the
ones sacrificed at 12 weeks. After animals were euthanized
(4, 8, and 12 weeks after surgery), calvaria specimens were
placed in 10% formalin for 7 days, and then transferred to
70% isopropanol for mCT scanning.
lCT of surgical specimens
The mCT scanning (Scanco Medical mCT 40) was per-
formed. The X-ray parameters were 70 kVp at 114mA with a
200 ms integration time. The image matrix size was
2048 · 2048 with acquired 2000 projections over a 360 rota-
tion. A 20.5-mm-diameter tube, which allows a pixel size of
10 mm, was used. Acquisitions were made using cone beam
geometry and a Feldkamp filtered back projection recon-
struction algorithm was used to create the reconstructions.
For the analyses of the acquired images, the CTAn analyzer
software (Skyscan) was used. Three-dimensional images
were reconstructed through direct volume rendering from
the series of 2D projections.
Assessing mineral apposition rate
by fluorescence microscopy
Retrieved calvaria specimens were transferred to proces-
sing cassettes and dehydrated to evaluate for calcium min-
eral apposition. Briefly, specimens were then infiltrated with
increasing resin (Technovit; Heraeus Kulzer GmbH) con-
centrations for up to 100% for 23 days, as described by
previous studies.28 At the end of the infiltration process,
specimens were polymerized in fresh resin in a light poly-
merization device (Exakt; Exakt Apparatebau) and ce-
mented to plexiglass slides. Two 300-mm sections were cut at
the sagittal midline and lateral to midline of each defect.
Finally, each specimen slide was thinned and polished to
final sections of 50 mm. Calvaria specimens in slides were
visualized using a Nikon fluorescence microscope apparatus
with bright field, TRITC and FITC filters, and a Nikon
FIG. 3. Three-dimensional mCT view of calvaria defects (ventral aspect) 8 weeks postimplantation. (A) Empty defect–G1; (B)
poly(lactic-co-glycolic acid) (PLGA)–G2; (C) HAP-GEL–G4; (D) titanium dioxide (TiO2)-HAP-GEL–G5; (E) bone autograft–
G6; (F) TiO2-HAP-GEL + OD-MAPC–G7; (G) TiO2-HAP-GEL + MAPC–G8. White circle represents the limits of the 8-mm-
diameter defect area. Red arrows: regions of osteointegration. Color images available online at www.liebertpub.com/tea
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Eclipse Ti-U digital camera. Nikon NIS Elements software
was used to acquire and analyze fluorescent merged images
and measure the distance between fluorescent-labeled layers
where calcium mineral apposition occurred. The distance
between mineral apposition layers was measured at the in-
terface between the native bone and the implanted scaffold
(INBS), both anteriorly, posteriorly, medially, and laterally
with Nikon NIS Elements software tools.27 The mean dis-
tance of the four regions was subject to statistical analysis
and the overall mean distance was calculated for each rat.
The mineral apposition rate (MAR) at INBS or bone healing/
regeneration was calculated for 8 and 12 weeks by dividing
the overall mean distance by the interlabeling period of 32
and 60 days, respectively. The MAR at the porous areas was
determined by measuring the maximum length of all new
bone islands in pores labeled with calcein at postsurgical day
42. All bone lengths in porous areas were summed up to get
the final MAR for each animal.
Histological processing of calvaria specimens
to determine new bone tissue formation
and resorption activity
After fluorescence microscopy, calvaria specimen slides
were stained for 15 min with Stevenel’s blue and counter-
stained with Van Gieson for 3 min to visualize the formation
of NFB tissue as described.28 Images were acquired with an
Olympus DP12 camera, which was mounted in an Olympus
BX51 optical microscope (Olympus Optical Co., Ltd.). This
staining procedure allowed the visualization of collagen
Table 1. Top: Experimental Surgical Groups with Scaffolds/Grafts Only
Cell-free scaffold groups
G1 G2 G3 G4 G5 G6
Empty PLGA Collagen HAP-GEL TiO2-HAP-GEL Bone autograft
Cell-loaded scaffold groups
G7 G8
TiO2-HAPGEL + 15 · 104 OD-MAPCs TiO2-HAPGEL + 15 · 104 MAPCs
Bottom: Experimental surgical groups with scaffolds loaded with 10 cell aggregates/scaffold (15 · 104cells/scaffold). MAPCs: cells are at
undifferentiated stage.
MAPC, multipotent adult progenitor cell; OD-MAPCs, osteogenically differentiated MAPCs; PLGA, poly(lactic-co-glycolic acid); HAP-
GEL, hydroxyapatite-gelatin.
FIG. 4. Three-dimensional mCT view of calvaria defects (ventral aspect) 12 weeks postimplantation. (A) Empty defect–G1;
(B) PLGA–G2; (C) collagen–G3; (D) HAP-GEL–G4; (E) TiO2-HAP-GEL–G5; (F) bone autograft–G6; (G, H) TiO2-HAP-GEL
scaffold with: (G) OD-MAPCs–G7; and (H) MAPCs–G8. White circle represents the limits of the 8-mm-diameter defect area.
Red arrows: regions of osteointegration. Color images available online at www.liebertpub.com/tea
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fibers and connective tissue in green or green-blue, osteoid in
yellow-green, native bone in pink-light red, and NFB in in-
tense red-purple. The medial (central) sagittal sections were
chosen for bone histomorphometric analysis. Stitched images
of each specimen acquired at 20 · magnification were created
using Adobe Photoshop CS6 (Adobe Systems, Inc.). The new
bone surface area (B.Ar.) and the total area of each defect
(T.Ar.) were obtained in pixels by using an image analysis
system (ImageJ software version 1.46R; NIH). The NFB was
calculated by determining the bone area (B.Ar./T.Ar.;%)
according to standardized protocols of the American Society
for Bone and Mineral Research.29
To evaluate for the osteoclast resorption activity,
12-week retrieved implanted HAP-GEL scaffolds were
fixed, decalcified, embedded in paraffin, cut to 6-mm
sections, and mounted on glass slides. The osteoclast re-
sorption activity was evaluated using the tartaric acid-
resistant acid phosphatase (TRAP) staining kit according
to previous studies.30 Blood smears were used as positive
controls. Slides not treated with TRAP were used as neg-
ative controls.
Statistical analysis
Multiple student t-tests were performed in all experi-
ments, except for MAR where one-way ANOVA and the
Tukey-Kramer method were used for multiple statistical
comparisons using JMP9 software (SAS Institute). Statistical
significance was defined at p < 0.05.
Results
Structural strength and porosity of preimplanted
HAP-GEL scaffolds
Before in vivo implantation in calvaria defects, the developed
macroporous TiO2-HAP-GEL scaffolds had a mean compres-
sive strength (13.8 MPa) and porosity (34.3%) (Table 2). These
properties resembled the ones found in natural calvaria bone
and were superior to collagen. As a result, TiO2-HAP-GEL
scaffolds provided the strength to support the skull’s structure
and were deemed feasible for the rat calvaria regeneration
model.
Retaining viable and osteogenic MAPC
aggregates in scaffolds
Before loading cell aggregates into macroporous TiO2-
HAP-GEL scaffolds, MAPC aggregates were tested in vitro
during 5 weeks of culture to confirm their osteogenic dif-
ferentiation capabilities by using in TEM. Abundant min-
eralization with spindle-like crystals was observed in TEM
of MAPC aggregate matrices (Fig. 2A). The encountered
osteogenic aggregates were then loaded into the macro-
porous TiO2-HAP-GEL scaffolds to assess cell viability. The
majority of cells within the scaffold were found metaboli-
cally active (as indicated by red fluorescence, Fig. 2B) with
scaffold macropores retaining 50–300 mm MAPC aggre-
gates. In summary, TiO2-HAP-GEL scaffolds not only pro-
vided the appropriate strength, but also hosted viable
osteogenic MAPC aggregates. Consequently, MAPC-loa-
ded scaffolds were feasible to be implanted in the calvaria
regeneration model.
lCT analysis of calvaria defects
after scaffold implantation
After 4 weeks of in vivo implantation, few areas of tissue
growth could be observed within the defect as per 3D mCT
images. (Supplementary Fig. S1A–D; Supplementary Data
are available online at www.liebertpub.com/tea). All HAP-
GEL-treated groups (with/without titania) had radiopacities
in defects since scaffolds were composed of inherently radi-
opaque HAP (Supplementary Fig. S1C, D). The radiopacities
associated with the above scaffolds and with natural bone
had overlapping thresholds, which made it unfeasible to
measure NFB using the mCT images with the current reso-
lution of 10mm/pixel.
Tomographic 3D images from calvaria specimens at later
postimplantation times, 8 and 12 weeks, can be observed in
Figures 3 and 4. At 8 weeks, the calvaria defect area was
partially filled with thin layers of radiopaque bone-like
tissue (RBT) in the periphery and central part of the defect
in the empty (G1) and PLGA (G2) groups (Fig. 3A, B).
Furthermore, TiO2-HAP-GEL (G5) had more regions of
osteointegration at INBS than HAP-GEL without titania
(G4) (Fig. 3C, D), suggesting that titania additives can in-
crease bone ingrowth in HAP-GEL biomaterial surfaces.
TiO2-HAP-GEL scaffolds with OD-MAPCs (G7) also had
more osteointegration, when compared to TiO2-HAP-GEL
only (G5) (Fig. 3D, F).
At 12 weeks postimplantation, calvaria defects without a
scaffold (G1), and with PLGA (G2), collagen (G3) were still
< 50% filled with RBT (Fig. 4 A–C). The HAP-GEL scaffold
with titanium (G5) had considerable osteointegration at
INBS (red arrows in Fig. 4E) compared to titanium-free HAP-
GEL (G4, Fig. 4D). Defects with cell-loaded TiO2-HAP-GEL
showed that OD-MAPCs promote greater osteointegration,
bone bridging, and narrowing of the defect than undiffer-
entiated MAPCs at 8 and 12 weeks (Fig. 3G, F, and Fig. 4G,
H). As expected, the calvaria defect was nearly completely
filled with RBT when an autograft (positive control) was
implanted (Fig. 4F).
Mineral apposition rate
Bone regeneration was also determined by assessing the
MAR at the INBS and also at the porous areas. The MAR at
Table 2. Ultimate Compressive Strength and Porosity
of the Calvaria Natural Bone Specimens
and of the Preimplanted Scaffolds
Specimens/Scaffolds




24.5 – 8.3 MPa 13.8 – 4.5 MPa* 0 – 0.1 MPa**
Pore size (mm) 0.64 – 0.4 1.52 – 0.8* N/A
Porosity (%) 22.9% 34.3%* N/A
The preimplanted macroporous TiO2-HAP-GEL scaffolds and the
collagen scaffolds were fabricated to be shaped to the in vivo
calvaria critical-size defect. Data are shown as mean – SD of four to
five independent experiments.*Denotes no statistical difference
when compared to calvaria bone; **p < 0.01 when statistically
compared to TiO2-HAP-GEL and calvaria bone. N/A: not applicable
(since collagen is radioque and cannot be analyzed by using mCT).
1808 FERREIRA ET AL.
INBS was evaluated 8 and 12 weeks postimplantation (be-
tween day 10 and 42 and day 10 and 70; in Fig. 5A, C) and
was found significantly higher for TiO2-enriched HAP-GEL
(G5) scaffolds (n = 3; p < 0.01), when compared to all cell-free
scaffolds, including HAP-GEL (G4). In addition, MAR with
TiO2-HAP-GEL was comparable to bone autograft at 8 weeks
(G6, positive control) ( p = 0.09), but not at 12 weeks post-
implantation. Therefore, TiO2-HAP-GEL (G5) scaffolds were
greatly advantageous in terms of bone healing, only compa-
rable to the current clinical gold standard (G6). In Figure 5A
and C, when OD-MAPCs were loaded into TiO2-HAP-GEL
(G7), the MAR increased significantly at the INBS (n = 3,
p = 0.0015). This bone-healing effect did not occur when un-
differentiated MAPCs (G8) were added into TiO2-enriched
scaffolds (n = 3; p = 1.0). In summary, the TiO2-HAP-GEL
constructs with OD-MAPCs had superior bone regeneration,
only comparable to bone autograft (n = 3; p = 0.4383). Con-
sistently with these findings, mineral apposition was also
significantly increased in the porous areas of TiO2-HAP-GEL
scaffolds loaded with cells, but not on those without (Fig. 5B).
New bone tissue formation
After 8 and 12 weeks postimplantation on calvaria defects,
NFB tissue was evaluated quantitatively and qualitatively
after staining of undecalcified samples, allowing visualiza-
tion of collagen fibers and connective tissue (green-blue),
osteoid (yellow-green), native bone (pink-light red), and NFB
(red-purple).
In Figure 5D, quantitative bone histomorphometry can be
perceived and compared to a more dynamic bone histo-
morphometric value such as MAR at 12 weeks post-
implantation (Fig. 5C). %NFB was significantly greater in
TiO2-HAP-GEL (G5) scaffolds when compared to other cell-
free scaffolds (G2, G3, G4), but not with cell-loaded scaffolds
TiO2-HAP-GEL (Fig. 5D). The autograft (G6) had the least
%NFB among all groups.
In qualitative studies, at lower magnification, a thin layer
of NFB (red-purple) was observed in the defect of the empty
and PLGA groups, G1 and G2, respectively (Fig. 6A, B). In
TiO2-HAP-GEL (G5) scaffolds, regions of osteointegration
with NFB tissue (red-purple) were visualized in the INBS
and inside the macroporous areas at higher magnification
(Fig. 6E, E1, E2), which were not abundant in HAP-GEL (G4)
(Fig. 6D, D1, D2). Unlike undifferentiated (Fig. 6G, G1, G2),
OD-MAPCs with TiO2-HAP-GEL (G5) scaffolds, showed
regions of osteointegration with NFB tissue (red-purple) in
the INBS (Fig. 6F, F1) and also NFB, osteoid, and collagen
fibers (blue-green) forming inside the scaffold macropores
(Fig. 6F2). The bone autograft (G6) had the defect largely
filled with NFB, as expected (Fig. 6C).
After 12 weeks postimplantation, calcium apposition as-
sessed by calcium fluorescence labeling (Fig. 7) and bone-
specific staining (Fig. 8) confirmed that calvaria defects with
TiO2-HAP-GEL scaffolds plus OD-MAPCs (G7) were the only
alloplastic constructs completely filled with newly mineral-
ized tissue (white arrows, Fig. 7F) and NFB (black arrows, Fig.
8F), similar to the autograft-treated defect (Fig. 8H and 9H).
Resorption activity after TiO2-HAP-GEL implantation
Ideally, scaffolds used in bone regeneration should be
gradually resorbed by the osteoclasts and replaced by new
bone. Therefore, after 12 weeks postimplantation, the oste-
oclast resorption activity at TiO2-HAP-GEL (G5) scaffolds
was assessed by TRAP staining (Fig. 9). The implanted TiO2-
HAP-GEL scaffolds exhibited regions of osteoclast resorption
as indicated by the purple-maroon areas in the INBS (black
arrows in Fig. 9A) like in previous studies.31,32
Discussion
In this study, a macroporous TiO2-HAP-GEL scaffold
for in vivo implantation was successfully fabricated and
shaped into nonload-bearing calvaria CSD. The pre-
implanted TiO2-HAP-GEL scaffolds had a final compressive
strength of 13.8 – 4.5 MPa, which is higher than the value
registered for the human trabecular bone in load-bearing
areas (5.6 – 3.8 MPa in the femur and 2.22 – 1.42 MPa in the
tibia)33,34 (Table 2). The strength of the scaffold was attrib-
uted to the diameter (700–800 mm) of the HAP-GEL trusses
extruded from the syringe nozzle. Moreover, macroporous
TiO2-HAP-GEL scaffolds retained viable OD-MAPC aggre-
gates with a 300mm maximum size (Fig. 2B). Consequently,
this tissue-engineered construct was deemed appropriate to
implant in the calvaria regeneration model.
After implantation in calvaria, cell-free scaffolds did not
appear to generate a radiopaque bone-like tissue after 4
weeks. The radiopacity of the HAP phase limited this eval-
uation. However, after 8 weeks postimplantation, TiO2-
HAP-GEL scaffolds promoted both osteointegration and
filling of the 8-mm CSD at the periphery, in the interface
INBS. Other cell-free scaffolds (like PLGA and collagen)
produced a very thin radiopaque tissue mainly at the pe-
riphery. The scarce NFB seen in PLGA may be related to the
acidity of the PLGA degradation byproducts during their
fast hydrolysis, which has been reported to induce an in-
flammatory reaction and impair bone healing.26 Likewise,
the cell-free collagen sponge had poor NFB tissue in CSD,
and thus, a modest effect on bone regeneration. This poor
collagen-related effect has been recently reported at CSD in
rat fibulas.9 In this latter report, researchers found that cell-
free collagen sponges have a very limited microvascular
network in both fracture healing and CSD models, unlike
HAP-based constructs.9
Results found here with the implanted cell-free TiO2-
HAP-GEL were further confirmed within the undecalcified
sections with NFB-specific staining and after evaluating the
MAR. The HAP-GEL without TiO2 additives had signifi-
cantly less MAR, osteointegration, and NFB in the porous
areas than the HAP-GEL enriched with TiO2. Similar obser-
vations have been reported in several different TiO2 dental
implant surfaces in in vitro and in vivo rat tibia studies.11,35–38
The proposed mechanism of titanium-associated osteo-
induction is thought to be related to hydroxyl groups and
calcium ions present in TiO2 surfaces. These hydroxyl
groups may well promote adsorption of calcium-binding
extracellular matrix proteins (e.g., alkaline phosphatase)
and RGD-specific peptide sequences (e.g., fibronectin, bone
sialoprotein).12,39
Interestingly, in OD-MAPCs loaded TiO2-HAPGEL scaf-
folds, several areas of osteointegration were observed after 8
and 12 weeks. Furthermore, mineralized NFB tissue was
seen in the pores and filled the defect length com-
pletely (Figs. 7 and 8), unlike scaffolds with undifferentiated
HYDROXYAPATITE SCAFFOLDS WITH CELL AGGREGATES FOR BONE REGENERATION 1809
FIG. 5. Mineral apposition
rate (MAR) and newly
formed bone (NFB). MAR
was determined at 8 weeks
(A, B) and 12 weeks (C), and
NFB at 12 weeks (D) after
implantation of scaffolds
(with and without cells) and
autografts. (A, C) At the in-
terface native bone scaffold
(INBS). (B) At the porous ar-
eas on the macroporous scaf-
folds. Data are shown as
mean – SD of three indepen-
dent experiments. *p < 0.01
when statistically compared
to cell-free scaffolds (G1, G2
and G4). #p < 0.05 when sta-
tistically compared to all
groups. n.s.: not significant
comparison. **p < 0.05 when
compared to cell-free scaf-
folds (G4 and G5). ***p < 0.05
when compared to cell-free
scaffolds and autografts (G2,
G3, G4, G6), but not signifi-
cant when compared to G7
and G8. Color images avail-
able online at www
.liebertpub.com/tea
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FIG. 6. NFB tissue after 8 weeks
postimplantation. The following
experimental groups were im-
planted: (A) G1: empty; (B) G2:
PLGA; (C) G6: bone autograft; (D)
G4: HAP-GEL; (E) G5: TiO2-HAP-
GEL; (F) G7: TiO2-HAP-GEL + DD-
MAPC; (G) G8: TiO2-HAP-GEL +
MAPC. All calvaria anteroposterior
sagittal cross sections shown here
were stained with Stevenel’s blue
and van Gieson. D1–G1 and D2–G2
squares were the selected regions
for higher magnification shown in
the inferior panel. A–G: Mag. 40 · ;
D1–G1: Mag. 100 · ; D2–G2: Mag.
200 · . Color images available
online at www.liebertpub.com/tea
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MAPCs. In addition, bone regeneration by MAR at the INBS
was significantly greater in differentiated than in undiffer-
entiated MAPCs. This dichotomy between in vivo bone-
healing effects of undifferentiated and osteogenically
differentiated adult stem cells has also been recently re-
ported.20 In this latter report, osteogenically differentiated
adipose-derived MSCs induced significantly more bone re-
generation than undifferentiated cells after 6 weeks in cal-
varia CSD.20 Previous to implantation, the differentiation
conditions for committing MAPCs to osteoprogenitor cells
in vitro have required long culture periods, as in differenti-
ation of human embryonic stem cells into mesenchymal
FIG. 7. Newly formed min-
eralized tissue in calvaria
CSD after 10 days (red layers)




groups were implanted: (A)
G1: empty; (B) G2: PLGA; (C)
G3: collagen; (D) G4: HAP-
GEL; (E) G5: TiO2-HAP-GEL;
(F) G7: TiO2-HAP-GEL + DD-
MAPC; (G) G8: TiO2-HAP-
GEL + MAPC; (H) G6: bone
autograft. All represent cal-
varia anteroposterior mid-
sagittal cross sections labeled
in vivo with Alizarin Red (day
10) and calcein (day 60).
White arrows indicate the
mineralized NFB tissue filling
the CSD area. Mag. 40 · .
Color images available online
at www.liebertpub.com/tea
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precursors.5,40–42 However, to satisfy the demand of high
osteoprogenitor cell numbers to regenerate large skeletal
defects via a tissue-engineered approach, novel aggregate
culture conditions were used here to assure a consistent
MAPC osteogenic differentiation on a large scale.17 More
than 1000 progenitor cells/cm3 have been required for bone
healing to occur.43 Here 15 · 104 cells were scaffold-seeded
(surpassing the required number) and contributed to the
complete healing observed in calvaria defects.
Significant differences in MAR were found at 8 and 12
weeks between TiO2-HAP-GEL with OD-MAPCs and all
other groups (excluding the autograft group, Fig. 5A–C).
Despite the significance of the in vivo outcomes, a larger
sample size may be necessary in future studies (n > 3). The
sole contribution of OD-MAPCs to the newly engineered
TiO2-HAP-GEL scaffold is debatable because new bone
formation assessed by red-purple color in bone histomor-
phometry indicated that bone healing in defects with TiO2-
HAP-GEL is similar when comparing without and with
MAPC/OD-MAPCs (Fig. 5D). However, this histomorpho-
metry method based on a very similar range of colors (pink,
red, purple) requires a subjective analysis, which has its
limitations.29,44 This color-method did not allow us to eval-
uate properly the new lamellar bone in the trabeculae and
Haversian system, particularly on the autograft group,
which reflected on its very low values of bone healing. On
the contrary, MAR is a more dynamic and objective bone
histomorphometric marker that considers the time-course
bone remodeling activity, and relies on two very distinct
fluorescent colors (red versus green).27,29 As such, high MAR
values (6–8mm/day) were expected for the autograft.
In in vivo reports using allogeneic cell sources, the re-
cruitment of host osteoprogenitor cells by allogeneic adult
stem cells similar to MAPCs has been documented and
found crucial for bioengineering new bone.45 In addition,
allogeneic adult stem cells can be defect-retained for more
than 9 weeks following implantation,46 although these
findings are species dependent.45 Species-specific differences
do exist in the regulation of the immunity, in the mechanism
of bone formation, or in the site of implantation. In recent
literature, higher ratios of M2/M1 macrophages concomi-
tantly with an absence of a foreign body response have been
found with scaffolds having 30–40-mm pores when com-
pared to hosts with nonporous implants.47 In this study,
TiO2-HAP-GEL scaffolds had 34% porosity with 1.52 – 0.8-
mm pores and were not engineered in vitro as in other
studies48 reporting a M1 predominant immune response (to
engineered in vitro matrices); therefore, we would expect to
have no foreign body response and a predominant M2
macrophage activity. Moreover, human MAPCs were re-
cently found safe for clinical trials for treatment of graft-
versus-host disease (ClinicalTrials.gov NCT00677859,
NCT00677222). Despite these facts, we believe that it would
be beneficial to assess the M1/M2 host response in future
studies particularly when using allogeneic (nonautologous)
MAPC transplants.48,49 The immune rejection mechanism
can start between day 3 and day 8 after implantation of al-
logeneic stem cells.45 In our previous studies, we found no
rejection-associated tissue necrosis or mixed lymphocytic
reaction 10 days after implantation of OD-MAPCs.5 In fact,
OD-MAPCs were found growing in HAP porous areas be-
tween day 4 and 10 in calvaria defects.
FIG. 8. NFB tissue in calvaria CSD 12 weeks post-
implantation of scaffolds/cells and autografts. The following
experimental groups were implanted: (A) G1: empty; (B) G2:
PLGA; (C) G3: collagen; (D) G4: HAP-GEL; (E) G5: TiO2-
HAP-GEL; (F) G7: TiO2-HAP-GEL + DD-MAPC; (G) G8:
TiO2-HAP-GEL + MAPC; (H) G6: bone autograft. All calvaria
anteroposterior midsagittal cross sections shown here were
stained with Stevenel’s blue and van Gieson. Black arrows
indicate the NFB tissue filling the CSD area. Mag. 40 · . Color
images available online at www.liebertpub.com/tea
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Clinical advantages of HAP-based constructs for bone
regeneration are many and include, a decreased potential for
infection and elimination of the necessity of a donor site.50
Postsurgical complications are minor and are generally as-
sociated with the slow HAP degradation.31,32,50 In this study,
the TiO2-HAP-GEL scaffold was degraded into smaller
pieces after 12 weeks, and the host TRAP activity was
abundantly present surrounding the biomaterials (Fig. 9).
However, the nonporous base used (for the scaffold reten-
tion) may take more time to degrade, particularly on HAP-
GEL scaffolds (without TiO2), since these inherently possess
greater amount of the aminosilane binder or crosslinker.6 In
addition, higher concentrations of the aminosilane may re-
duce the porosity and limit the migration of osteoprogenitor
cells residing on the dorsal and ventral periosteum in this
calvaria model.6,51
The formation of a microvascular network in porous
scaffolds was not the main goal of this study, and therefore,
it was not thoroughly evaluated. However, in the future,
these HAP-GEL constructs may require loading of endothe-
lial progenitor cells to generate microvascularization and
promote a faster regeneration.9
In conclusion, the fabrication of a rigid macroporous TiO2-
enriched HAP-GEL scaffold was found feasible for bone re-
generation applications in calvaria defects. After 12 weeks
postimplantation, TiO2-HAP-GEL scaffolds loaded with OD-
MAPCs promoted osteointegration, NFB in the macroporous
areas and significantly enhanced bone regeneration. Also,
TiO2-HAP-GEL scaffolds had greater bone regeneration than
other cell-free scaffolds (PLGA, collagen, and HAP-GEL).
Finally, constructs with TiO2-HAP-GEL scaffolds and OD-
MAPCs had a greater bone healing than the cell-free
TiO2-HAP-GEL with complete closure of the defect. Thus,
TiO2-HAP-GEL constructs with OD-MAPCs can be applied
in craniofacial bone regeneration models (e.g., calvaria) to
enhance bone healing and regeneration. These constructs
will need further testing in load-bearing models.
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